IMPORTANCE Merkel cell carcinoma (MCC) is an aggressive skin cancer that is associated with poor survival outcomes in patients with distant metastatic disease. Results of part A of the JAVELIN Merkel 200 trial (avelumab in patients with Merkel cell carcinoma) showed that avelumab, an anti-programmed cell death ligand 1 (PD-L1) antibody, demonstrated efficacy in second-line or later treatment of patients with metastatic MCC (mMCC).
M
etastatic Merkel cell carcinoma (mMCC) is a rare, aggressive skin cancer with poor survival. 1 Merkel cell carcinoma (MCC) is associated with Merkel cell polyomavirus infection, UV light exposure, and advanced age; additional risk factors include fair skin and male sex. 1,2 Despite MCC being a chemosensitive disease, durable responses are rare. 3 In retrospective studies of first-line chemotherapy in patients with mMCC, median progression-free survival (PFS) was 3.1 to 4.6 months, 4,5 highlighting the need for improved treatment options. Programmed cell death ligand 1 (PD-L1) is expressed on MCC tumor cells and in the MCC tumor microenvironment, indicating a potential role for immune checkpoint inhibitors such as anti-PD-L1 and anti-programmed cell death 1 (PD-1) antibodies. 6-8 Trials involving anti-PD-1/PD-L1 antibodies have shown clinical activity and durable responses in patients with advanced MCC. 9-11 Based on findings from the phase 2 trial of avelumab, an IgG1 anti-PD-L1 monoclonal antibody, in patients with MCC (JAVELIN Merkel 200), avelumab became the first treatment for patients with mMCC to receive approval in the United States, the European Union, and Japan. 11-15 Herein, we report data from an interim analysis of avelumab as first-line treatment in patients with mMCC.
Methods
In part B of the ongoing JAVELIN Merkel 200 trial (start date, April 15, 2016), eligible patients had stage IV mMCC and had not received prior systemic therapy for metastatic disease. Patients with autoimmune conditions were excluded. The primary end point was durable response, defined as an objective response with a duration of at least 6 months according to Response Evaluation Criteria in Solid Tumors version 1.1, per independent review. Secondary end points included best overall response, duration of response, PFS, and safety. PD-L1 expression and viral status will be investigated in a future analysis. Time-to-event end points were analyzed by KaplanMeier methods; medians were calculated with corresponding CIs using the Brookmeyer-Crowley method. Additional eligibility criteria, procedures for statistical analysis, and study design information for JAVELIN Merkel 200 have been previously reported. 11 Patients provided written informed consent to enroll in the protocol with institutional review board approval from the participating centers (eTable 1 in the Supplement) and in accordance with international good clinical practice standards.
Results
From April 15, 1016, to March 24, 2017, 39 of 112 patients initiated avelumab treatment ( Figure 1) , with a median follow-up of 5.1 months (range, 0.3-11.3 months). Thirty patients were men, and 9 were women, and median age was 75 years (range, 47-88 years); additional demographics are described in eTable 2 in the Supplement. . In this prespecified interim analysis, safety was assessed in 39 patients who received at least 1 dose of avelumab, and efficacy was evaluated in 29 patients with at least 3 months of follow-up. Efficacy was also assessed in a subset of 14 patients with at least 6 months of follow-up. Of the 29 patients with at least 3 months of follow-up, 4 (13.8%) had a complete response and 14 (48.3%) had a partial response, resulting in a confirmed objective response rate of 62.1% (95% CI, 42.3%-79.3%) ( Table) ; 3 additional patients (10.3%) had stable disease. Median time to response was 6.1 weeks (range, 5-17 weeks), with 16 of 18 responses (88.9%) observed at the first scheduled postbaseline assessment approximately 6 weeks from the start of treatment (Figure 2A) . Among the 14 patients with at least 6 months of follow-up, the confirmed objective response rate was 71.4% (95% CI, 41.9%-91.6%). Four patients (28.6%) had a complete response, and 6 (42.9%) had a partial response; an additional patient (7.1%) had stable disease.
Responses were ongoing at the time of analysis in 14 of 18 responders (77.8%), and the median duration of response was not estimable (range, 1.2-8.3 months). Based on KaplanMeier estimates, the proportion of responses with a duration Meaning First-line avelumab monotherapy in patients with metastatic Merkel cell carcinoma was associated with early responses, high response rates, and a manageable safety profile.
of at least 3 months was 93% (95% CI, 61%-99%); those with a response duration of at least 6 months, 83% (95% CI, 49%-96%). In this still-maturing cohort, the 3-month PFS rate was 67% (95% CI, 48%-80%), and median PFS was 9.1 months (range, 1.9 to not estimable) (Table) . Twenty-one of 30 patients (70%) with a follow-up tumor assessment available were reported to have at least 30% reduction in target lesions from baseline ( Figure 2B -C). Among 39 patients evaluable for safety, 28 (71.8%) had a treatment-related adverse event (TRAE), and 8 patients (20.5%) had a grade 3 TRAE (eTable 3 in the Supplement). No grade 4 TRAEs or treatment-related deaths occurred. Treatmentrelated infusion-related reactions occurred in 9 patients (23.1%) and were grade 3 in 1 patient (2.6%). Grade 1 immune-related adverse events occurred in 6 patients (15.4%) (eTable 4 in the Supplement). Avelumab therapy was permanently discontinued because of a TRAE in 1 patient each with cholangitis, elevated aspartate aminotransferase and alanine aminotransferase levels, paraneoplastic syndrome and gait disturbance, and paraneoplastic encephalomyelitis and polyneuropathy and in 2 patients with infusion-related reaction (6 patients [15.4%]). Of these 6 patients, 1 had a complete response ongoing at the time of analysis, 1 had a partial response assessed before the start of subsequent anticancer therapy, and 1 had stable disease before the start of subsequent anticancer therapy.
Discussion
In this prespecified interim analysis of patients with mMCC, firstline avelumab treatment was associated with early and durable responses and a manageable safety profile. The confirmed objective response rate is consistent with results of previous studies of immune checkpoint inhibitors for first-line treatment of a Includes 29 patients with at least 3 and 14 with at least 6 months of follow-up.
b Patient died before tumor assessment due to an adverse event unrelated to treatment with avelumab.
c Includes 18 patients with at least 3 and 10 with at least 6 months of follow-up. MCC. 9,10 To our knowledge, this study is the first to investigate immune checkpoint inhibitors exclusively in patients with stage IV MCC. Two anti-PD-1 antibodies have been investigated for the first-line treatment of patients with advanced MCC, including nivolumab in patients with stages II to IV MCC and pembrolizumab in patients with stages IIIB to IV MCC.
9,10
Before the approval of avelumab, chemotherapy was commonly used to treat mMCC; it is now recommended for patients who are not candidates for immunotherapy.
2 In a systematic literature review, first-line chemotherapy produced high initial response rates (range, 53%-61%); however, response durability was short (range, 2.8-8.0 months), and treatment was associated with considerable toxic effects. 3 We report promising evidence of response durability among patients with an objective response and at least 3 months of follow-up, given that 83% of patients are estimated to have responses lasting at least 6 months. Our median PFS of 9.1 months for patients receiving first-line treatment exceeds that previously reported with chemotherapy. 4,5 Our safety analysis showed that avelumab was generally tolerable. These findings suggest overall improvement of outcomes with immune checkpoint inhibitors vs chemotherapy in patients with mMCC. Our results corroborate prior evidence from part A of the JAVELIN Merkel 200 study, 11 which showed that previously treated patients with fewer prior lines of treatment experienced more favorable outcomes. JAVELIN Merkel 200 is the largest prospective clinical trial performed in stage IV distant mMCC to date and is actively enrolling participants in part B of the study. Findings from this trial led to approval of avelumab for the treatment of mMCC in the United States, the European Union, and Japan.
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Strengths and Limitations
Analysis of PFS in the present study is based on limited follow-up in some patients and may evolve as the minimum follow-up extends; longer-term follow-up will also permit meaningful analysis of overall survival. Because data with extended follow-up have not been published for nivolumab and pembrolizumab, comparisons of long-term survival outcomes, TRAEs, and economic impact with other immune checkpoint inhibitors for first-line treatment were not possible. 9,10 Future analysis of first-line avelumab treatment will investigate whether biomarkers, such as PD-L1 expression or viral status, correlate with response to treatment.
Conclusions
First-line avelumab monotherapy had antitumor activity and a manageable safety profile in patients with mMCC. Maturing PFS data suggest durable responses, supporting avelumab as a standard of care in patients with mMCC. 1 (2.6) 1 (2.6) Cholangitis 1 (2.6) 1 (2.6) Elevated AST 1 (2.6) 1 (2.6) Gait disturbance 1 (2.6) 1 (2.6) Paraneoplastic encephalomyelitis 1 (2.6) 1 (2.6) Polyneuropathy 1 (2.6) 1 (2.6) Paraneoplastic syndrome 1 (2.6) 1 (2.6) Troponin increased 1 (2.6) 1 (2.6) ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPK, creatine phosphokinase. Adverse events of any grade in at least 5% of patients or any grade 3 adverse event. a One event of pruritus and 2 events of rash maculo-papular were also considered immunerelated adverse events.
